Press & News

ViewReleaseInStandardHtml

Boule Diagnostics Interim report January-September 2015

Increased sales and a higher gross margin

Net sales for third quarter 2015 increased by 20.7 percent to SEK 88.8 (73.6) million. Adjusted for exchange rate fluctuations, principally in respect of USD, sales increased by 4.2 percent compared to the same quarter in 2014. For the period January-September, net sales increased by 12.2 percent to SEK 243.0 (216.6) million. Adjusted for exchange rate fluctuations, this represents a decrease in sales of 1.8 percent.

Gross margin for third quarter 2015 amounted to 46.6 percent (44.2). Compared to the previous year, this increase can be mainly ascribed to increased sales of consumables and a stronger USD.

Consumables, reagents and blood controls continued to increase their proportion of sales during the third quarter. In total, they represented 57 percent of our net sales during the quarter, compared to 55 percent for the same period in 2014. This upward trend has contributed to a more stable net sales and higher gross margins.

Operating profit for third quarter amounted to SEK 8.9 (10.0) million.

For more information, please contact:
Ernst Westman, President and CEO, Boule Diagnostics AB, +46 708-60 88 63

About Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) is a company that develops, manufactures and markets instruments and consumables for hematology diagnostics. The company aims towards small and medium-sized hospitals, clinics and laboratories as well as other diagnostics companies within the human and veterinary market of hematology diagnostics. The company is an international group of companies with subsidiaries in Sweden, the US and China. Boule Diagnostics’ share were listed on NASDAQ Stockholm in 2011. www.boule.se